Investigation of the management and risk of febrile neutropenia associated with chemotherapy in the urological field

A multicenter, retrospective analysis

Koichiro Wada, Ryuta Tanimoto, Hiroyuki Nose, Shinya Uehara, Toyohiko Watanabe, Hiroshi Hayami, Shingo Nagai, Mitsuru Yasuda, Takashi Deguchi, Keisuke Shigeta, Satoshi Yazawa, Eiji Kikuchi, Mototsugu Oya, Jiro Hashimoto, Teruhisa Uehara, Yuichiro Kurimura, Yoshiki Hiyama, Satoshi Takahashi, Taiji Tsukamoto, Takehiko Sho & 11 others Ryoichi Hamasuna, Jun Miyazaki, Yoshikazu Togo, Rikiya Taoka, Atsushi Nakao, Shingo Yamamoto, Kanao Kobayashi, Akio Matsubara, Kiyohito Ishikawa, Hiromi Kumon, Tetsuro Matsumoto

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In Japan, chemotherapy for urogenital malignant diseases is commonly performed by urologists and febrile neutropenia (FN) is one of the major adverse events associated with chemotherapy, however, few reports exist from the urological field about FN. In this present study, a total of 883 courses of chemotherapy (326 patients) performed from 2010 to 2011 at 10 University Hospitals were retrospectively reviewed. The regimens were GC (gemcitabine and cisplatin), GCP (gemcitabine, cisplatin and paclitaxel) and M-VAC (methotrexate, vinblastine, doxorubicin, cisplatin) for urothelial carcinoma, and EP (etoposide and cisplatin) and BEP (bleomycin, etoposide and cisplatin) for testicular cancer. In 81 courses (9.2%, 66 patients; 20.2%) including FN, antimicrobials and granulocyte-colony stimulating factor (G-CSF) were administered in 69 courses (85.2%) and in 77 courses (95.1%), respectively. The MASCC risk-index score was evaluated in no more than 51 courses (63.0%) and 1 patient with 18 points on the MASCC score died due to myelotoxicity and infections. According to statistical investigations, FN is significantly more frequent in GCP and M-VAC than in GC (p = 0.0073,

Original languageEnglish
Pages (from-to)374-381
Number of pages8
JournalJapanese Journal of Chemotherapy
Volume62
Issue number3
Publication statusPublished - 2014

Fingerprint

gemcitabine
Febrile Neutropenia
Risk Management
Cisplatin
Drug Therapy
Vinblastine
Etoposide
Methotrexate
Doxorubicin
Bleomycin
Testicular Neoplasms
Granulocyte Colony-Stimulating Factor
Japan
Carcinoma
Infection

Keywords

  • Anticancer chemotherapy
  • Febrile neutropenia
  • Multicenter trial
  • Urology

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Investigation of the management and risk of febrile neutropenia associated with chemotherapy in the urological field : A multicenter, retrospective analysis. / Wada, Koichiro; Tanimoto, Ryuta; Nose, Hiroyuki; Uehara, Shinya; Watanabe, Toyohiko; Hayami, Hiroshi; Nagai, Shingo; Yasuda, Mitsuru; Deguchi, Takashi; Shigeta, Keisuke; Yazawa, Satoshi; Kikuchi, Eiji; Oya, Mototsugu; Hashimoto, Jiro; Uehara, Teruhisa; Kurimura, Yuichiro; Hiyama, Yoshiki; Takahashi, Satoshi; Tsukamoto, Taiji; Sho, Takehiko; Hamasuna, Ryoichi; Miyazaki, Jun; Togo, Yoshikazu; Taoka, Rikiya; Nakao, Atsushi; Yamamoto, Shingo; Kobayashi, Kanao; Matsubara, Akio; Ishikawa, Kiyohito; Kumon, Hiromi; Matsumoto, Tetsuro.

In: Japanese Journal of Chemotherapy, Vol. 62, No. 3, 2014, p. 374-381.

Research output: Contribution to journalArticle

Wada, K, Tanimoto, R, Nose, H, Uehara, S, Watanabe, T, Hayami, H, Nagai, S, Yasuda, M, Deguchi, T, Shigeta, K, Yazawa, S, Kikuchi, E, Oya, M, Hashimoto, J, Uehara, T, Kurimura, Y, Hiyama, Y, Takahashi, S, Tsukamoto, T, Sho, T, Hamasuna, R, Miyazaki, J, Togo, Y, Taoka, R, Nakao, A, Yamamoto, S, Kobayashi, K, Matsubara, A, Ishikawa, K, Kumon, H & Matsumoto, T 2014, 'Investigation of the management and risk of febrile neutropenia associated with chemotherapy in the urological field: A multicenter, retrospective analysis', Japanese Journal of Chemotherapy, vol. 62, no. 3, pp. 374-381.
Wada, Koichiro ; Tanimoto, Ryuta ; Nose, Hiroyuki ; Uehara, Shinya ; Watanabe, Toyohiko ; Hayami, Hiroshi ; Nagai, Shingo ; Yasuda, Mitsuru ; Deguchi, Takashi ; Shigeta, Keisuke ; Yazawa, Satoshi ; Kikuchi, Eiji ; Oya, Mototsugu ; Hashimoto, Jiro ; Uehara, Teruhisa ; Kurimura, Yuichiro ; Hiyama, Yoshiki ; Takahashi, Satoshi ; Tsukamoto, Taiji ; Sho, Takehiko ; Hamasuna, Ryoichi ; Miyazaki, Jun ; Togo, Yoshikazu ; Taoka, Rikiya ; Nakao, Atsushi ; Yamamoto, Shingo ; Kobayashi, Kanao ; Matsubara, Akio ; Ishikawa, Kiyohito ; Kumon, Hiromi ; Matsumoto, Tetsuro. / Investigation of the management and risk of febrile neutropenia associated with chemotherapy in the urological field : A multicenter, retrospective analysis. In: Japanese Journal of Chemotherapy. 2014 ; Vol. 62, No. 3. pp. 374-381.
@article{4cb0f5cef34f46d1984473ae2a81e103,
title = "Investigation of the management and risk of febrile neutropenia associated with chemotherapy in the urological field: A multicenter, retrospective analysis",
abstract = "In Japan, chemotherapy for urogenital malignant diseases is commonly performed by urologists and febrile neutropenia (FN) is one of the major adverse events associated with chemotherapy, however, few reports exist from the urological field about FN. In this present study, a total of 883 courses of chemotherapy (326 patients) performed from 2010 to 2011 at 10 University Hospitals were retrospectively reviewed. The regimens were GC (gemcitabine and cisplatin), GCP (gemcitabine, cisplatin and paclitaxel) and M-VAC (methotrexate, vinblastine, doxorubicin, cisplatin) for urothelial carcinoma, and EP (etoposide and cisplatin) and BEP (bleomycin, etoposide and cisplatin) for testicular cancer. In 81 courses (9.2{\%}, 66 patients; 20.2{\%}) including FN, antimicrobials and granulocyte-colony stimulating factor (G-CSF) were administered in 69 courses (85.2{\%}) and in 77 courses (95.1{\%}), respectively. The MASCC risk-index score was evaluated in no more than 51 courses (63.0{\%}) and 1 patient with 18 points on the MASCC score died due to myelotoxicity and infections. According to statistical investigations, FN is significantly more frequent in GCP and M-VAC than in GC (p = 0.0073,",
keywords = "Anticancer chemotherapy, Febrile neutropenia, Multicenter trial, Urology",
author = "Koichiro Wada and Ryuta Tanimoto and Hiroyuki Nose and Shinya Uehara and Toyohiko Watanabe and Hiroshi Hayami and Shingo Nagai and Mitsuru Yasuda and Takashi Deguchi and Keisuke Shigeta and Satoshi Yazawa and Eiji Kikuchi and Mototsugu Oya and Jiro Hashimoto and Teruhisa Uehara and Yuichiro Kurimura and Yoshiki Hiyama and Satoshi Takahashi and Taiji Tsukamoto and Takehiko Sho and Ryoichi Hamasuna and Jun Miyazaki and Yoshikazu Togo and Rikiya Taoka and Atsushi Nakao and Shingo Yamamoto and Kanao Kobayashi and Akio Matsubara and Kiyohito Ishikawa and Hiromi Kumon and Tetsuro Matsumoto",
year = "2014",
language = "English",
volume = "62",
pages = "374--381",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "3",

}

TY - JOUR

T1 - Investigation of the management and risk of febrile neutropenia associated with chemotherapy in the urological field

T2 - A multicenter, retrospective analysis

AU - Wada, Koichiro

AU - Tanimoto, Ryuta

AU - Nose, Hiroyuki

AU - Uehara, Shinya

AU - Watanabe, Toyohiko

AU - Hayami, Hiroshi

AU - Nagai, Shingo

AU - Yasuda, Mitsuru

AU - Deguchi, Takashi

AU - Shigeta, Keisuke

AU - Yazawa, Satoshi

AU - Kikuchi, Eiji

AU - Oya, Mototsugu

AU - Hashimoto, Jiro

AU - Uehara, Teruhisa

AU - Kurimura, Yuichiro

AU - Hiyama, Yoshiki

AU - Takahashi, Satoshi

AU - Tsukamoto, Taiji

AU - Sho, Takehiko

AU - Hamasuna, Ryoichi

AU - Miyazaki, Jun

AU - Togo, Yoshikazu

AU - Taoka, Rikiya

AU - Nakao, Atsushi

AU - Yamamoto, Shingo

AU - Kobayashi, Kanao

AU - Matsubara, Akio

AU - Ishikawa, Kiyohito

AU - Kumon, Hiromi

AU - Matsumoto, Tetsuro

PY - 2014

Y1 - 2014

N2 - In Japan, chemotherapy for urogenital malignant diseases is commonly performed by urologists and febrile neutropenia (FN) is one of the major adverse events associated with chemotherapy, however, few reports exist from the urological field about FN. In this present study, a total of 883 courses of chemotherapy (326 patients) performed from 2010 to 2011 at 10 University Hospitals were retrospectively reviewed. The regimens were GC (gemcitabine and cisplatin), GCP (gemcitabine, cisplatin and paclitaxel) and M-VAC (methotrexate, vinblastine, doxorubicin, cisplatin) for urothelial carcinoma, and EP (etoposide and cisplatin) and BEP (bleomycin, etoposide and cisplatin) for testicular cancer. In 81 courses (9.2%, 66 patients; 20.2%) including FN, antimicrobials and granulocyte-colony stimulating factor (G-CSF) were administered in 69 courses (85.2%) and in 77 courses (95.1%), respectively. The MASCC risk-index score was evaluated in no more than 51 courses (63.0%) and 1 patient with 18 points on the MASCC score died due to myelotoxicity and infections. According to statistical investigations, FN is significantly more frequent in GCP and M-VAC than in GC (p = 0.0073,

AB - In Japan, chemotherapy for urogenital malignant diseases is commonly performed by urologists and febrile neutropenia (FN) is one of the major adverse events associated with chemotherapy, however, few reports exist from the urological field about FN. In this present study, a total of 883 courses of chemotherapy (326 patients) performed from 2010 to 2011 at 10 University Hospitals were retrospectively reviewed. The regimens were GC (gemcitabine and cisplatin), GCP (gemcitabine, cisplatin and paclitaxel) and M-VAC (methotrexate, vinblastine, doxorubicin, cisplatin) for urothelial carcinoma, and EP (etoposide and cisplatin) and BEP (bleomycin, etoposide and cisplatin) for testicular cancer. In 81 courses (9.2%, 66 patients; 20.2%) including FN, antimicrobials and granulocyte-colony stimulating factor (G-CSF) were administered in 69 courses (85.2%) and in 77 courses (95.1%), respectively. The MASCC risk-index score was evaluated in no more than 51 courses (63.0%) and 1 patient with 18 points on the MASCC score died due to myelotoxicity and infections. According to statistical investigations, FN is significantly more frequent in GCP and M-VAC than in GC (p = 0.0073,

KW - Anticancer chemotherapy

KW - Febrile neutropenia

KW - Multicenter trial

KW - Urology

UR - http://www.scopus.com/inward/record.url?scp=84902342121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902342121&partnerID=8YFLogxK

M3 - Article

VL - 62

SP - 374

EP - 381

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - 3

ER -